Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31426773 | 1.00 | MAPT (0.33) | MAPTPDK2MMP2MMP9MMP8 | |
| SCHEMBL30613901 | 0.85 | MAPT (0.31) | MAPT | |
| SCHEMBL30613899 | 0.85 | MAPT (0.31) | MAPT | |
| Benzo[1,2,5]Thiadiazole SCHEMBL17075348 | 0.83 | MMP2 (0.38) | MAPTPDK2MMP2MMP9MMP8 | |
| SCHEMBL16019308 | 0.78 | PDK2 (0.34) | MAPTPDK2MMP2MMP9MMP8 | |
| SCHEMBL22402530 | 0.78 | PDK2 (0.34) | MAPTPDK2MMP2MMP9MMP8 | |
| SCHEMBL25444635 | 0.76 | PDK2 (0.37) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL22402534 | 0.76 | PDK2 (0.37) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL25444633 | 0.76 | PDK2 (0.37) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL5354304 | 0.76 | PDK2 (0.37) | PDK2MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250261553-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT | TOSOH CORPORATION (JP) | 2025-08-14 | — | — | US | disclosed |
| WO-2025089261-A1 | ORGANIC TRANSISTOR | 東ソー株式会社 | 2025-05-01 | — | — | WO | disclosed |
| EP-4516794-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM, AND ORGANIC SEMICONDUCTOR ELEMENT | Tosoh Corporation (JP) | 2025-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250261553-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT | CD99, SOAT2, SOAT1 | MAPT 402/4885PDK2 2659/4885MMP2 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.